13F filer · CIK 1910456
Lynx1 Capital Management LP
DORADO, PR · filing since Q4 2021 · last filing Aug 13, 2026
Reported value
$865.5M
+$232.8M vs prior
Positions
27
New / sold out
6 / 2
Added / reduced
6 / 7
Turnover
11.2%
buys $102.6M · sells $84.0M
Top-10 weight
98.8%
Biggest buys vs Q1 2026
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| Added | GH RESEARCH PLC | +2,500,000 | +23.2% | +$67.2M |
| Added | AGIOS PHARMACEUTICALS INC | +797,369 | +30.5% | +$29.6M |
| New | PLIANT THERAPEUTICS INC | +1,798,070 | – | +$2.0M |
| Added | C4 THERAPEUTICS INC | +327,789 | +4.7% | +$1.5M |
| Added | PROQR THRAPEUTICS N V | +452,927 | +661.3% | +$842.4K |
| Added | TRAWS PHARMA INC | +544,392 | +3610.5% | +$459.1K |
| New | FOGHORN THERAPEUTICS INC | +61,588 | – | +$300.5K |
| Added | PASSAGE BIO INC | +50,055 | +8.0% | +$244.3K |
| New | AVALO THERAPEUTICS INC | +10,100 | – | +$186.6K |
| New | NUVATION BIO INC | +16,029 | – | +$91.0K |
2 more rows. Subscribe for $29/month to see every row, download the data and use the API.
Biggest sells vs Q1 2026
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| Reduced | DENALI THERAPEUTICS INC | -1,868,645 | -99.4% | $-48.1M |
| Reduced | STOKE THERAPEUTICS INC | -725,269 | -15.2% | $-23.7M |
| Reduced | XENCOR INC | -518,204 | -96.6% | $-8.3M |
| Reduced | IMMATICS N.V | -193,737 | -89.3% | $-2.0M |
| Sold out | DESIGN THERAPEUTICS INC | -119,516 | -100.0% | $-1.3M |
| Reduced | PRECISION BIOSCIENCES INC | -34,647 | -3.5% | $-272.3K |
| Reduced | ENTRADA THERAPEUTICS INC | -33,083 | -15.6% | $-243.5K |
| Sold out | IBIO INC | -68,076 | -100.0% | $-129.3K |
| Reduced | CG ONCOLOGY INC | -200 | -0.6% | $-14.2K |
Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.
Reported value by quarter
Holdings · Q2 2026
| # | Security | Shares | Value | Weight |
|---|---|---|---|---|
| 1 | GH RESEARCH PLCORDINARY SHARES | 13,263,288 | $356.5M | 41.19% |
| 2 | CULLINAN THERAPEUTICS INCCOM | 8,963,500 | $163.2M | 18.86% |
| 3 | STOKE THERAPEUTICS INCCOM | 4,038,404 | $132.1M | 15.27% |
| 4 | AGIOS PHARMACEUTICALS INCCOM | 3,408,937 | $126.5M | 14.62% |
| 5 | C4 THERAPEUTICS INCCOM STK | 7,326,691 | $34.2M | 3.95% |
| 6 | KORRO BIO INCCOM | 1,538,296 | $20.3M | 2.34% |
| 7 | TSCAN THERAPEUTICS INCCOM | 8,019,148 | $7.9M | 0.91% |
| 8 | PRECISION BIOSCIENCES INCCOM NEW | 950,466 | $7.5M | 0.86% |
| 9 | NEUPHORIA THERAPEUTICS INCCOM | 875,328 | $3.8M | 0.44% |
| 10 | PASSAGE BIO INCCOM NEW | 673,759 | $3.3M | 0.38% |
17 more rows. Subscribe for $29/month to see every row, download the data and use the API.